OSE Immunotherapeutics SA

OSE Immunotherapeutics reported a revenue of €2.7 million in the latest period, while operating income was a loss of €37.5 million and net income was a loss of €37.4 million. The company's operating cash flow was negative at €34 million, indicating a significant cash outflow from operations. The liquidity position could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. Profitability metrics show a challenging financial position. The company is not generating positive returns, with a net loss of €37.4 million. The operating margin is negative at -1389%, and the net margin is also negative at -1385%. These figures are far below the industry median for profitability metrics, which typically show positive returns for companies in the biotechnology and medical research sector. The company's revenue is not segmented by product or geographic region in the available data, making it difficult to assess the concentration of revenue sources. However, the lack of segment data suggests that the company may be heavily reliant on a few key products or markets, which could pose a concentration risk. Looking ahead, the company's growth trajectory is uncertain. The latest financial data does not provide a clear indication of future revenue growth. Analysts have provided a mean price target of €10.60, with a median of €10.60 and a range from €8.20 to €13.00. The mean recommendation is 1.75, indicating a generally positive outlook, with 1 strong buy, 3 buy, and 0 hold ratings. The company's risk profile includes a low dilution potential, as per the risk assessment. However, the liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents. This uncertainty in liquidity could affect the company's ability to meet short-term obligations. Recent events include the publication of the latest financial snapshot, which shows continued losses and negative cash flow. No recent filings or transcripts were provided in the input data, so there is no additional information on recent strategic or operational developments.